Fate Therapeutics FATE
NASDAQ FATE
$2.36 -0.01 (-0.42%)
As of: Oct 1, 2026 · 9:33 AM EDT

Fate Therapeutics (FATE) Preferred Stock Liabilities (2012 - 2013)

Updated

Fate Therapeutics (FATE) posted Preferred Stock Liabilities of $56.53 million for Q3 2013.

Analysis

Fate Therapeutics (FATE) Preferred Stock Liabilities (2012 - 2013) Analysis & Trends

  • In prior years, Fate Therapeutics' Preferred Stock Liabilities was $50.31 million in FY2011.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Preferred Stock Liabilities (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 Fate Therapeutics 276.57 Mn 276.57 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2013 56.53 Mn
Dec 31, 2012 56.53 Mn
API Access

Fate Therapeutics Preferred Stock Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=preferred-stock-liabilities&ticker=FATE&period=max&api_key=YOUR_API_KEY